Filing Details
- Accession Number:
- 0000899243-19-014037
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-17 18:27:22
- Reporting Period:
- 2019-05-16
- Accepted Time:
- 2019-05-17 18:27:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586893 | Scott J Wolchko | C/O Fate Therapeutics, Inc.; 3535 General Atomics Court #200 San Diego CA 92121 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-05-16 | 14,335 | $1.63 | 389,216 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-05-16 | 2,298 | $18.46 | 386,918 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-05-16 | 12,037 | $19.54 | 374,881 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-05-16 | 14,335 | $0.00 | 14,335 | $1.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-02-08 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018.
- Represents the weighted average sale price of the shares sold ranging from $18.24 to $19.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $19.24 to $19.91 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- The shares subject to this option became fully vested and exercisable on October 4, 2015.
- Not applicable.
Billionaire Hedge Funds
